Taina Turpeenniemi-Hujanen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kyllönen Heli; Pasanen Anna Kaisa; Kuittinen Outi; Haapasaari Kirsi-Maria; Turpeenniemi-Hujanen Taina
Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
Bono P; Kellokumpu-Lehtinen P-L; Alanko T; Kokko R; Asola R; Turpeenniemi-Hujanen T; Jyrkkiö S; Kataja V; Leinonen M; Joensuu H
Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial.
Pennanen Heli; Kuittinen Outi; Soini Ylermi; Turpeenniemi-Hujanen Taina
Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Taina Turpeenniemi-Hujanen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kyllönen Heli; Pasanen Anna Kaisa; Kuittinen Outi; Haapasaari Kirsi-Maria; Turpeenniemi-Hujanen Taina
Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
Leukemia & lymphoma 2009;50(8):1301-7.
2009: Bono P; Kellokumpu-Lehtinen P-L; Alanko T; Kokko R; Asola R; Turpeenniemi-Hujanen T; Jyrkkiö S; Kataja V; Leinonen M; Joensuu H
Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(3):595-6.
2008: Pennanen Heli; Kuittinen Outi; Soini Ylermi; Turpeenniemi-Hujanen Taina
Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
European journal of haematology 2008;81(4):289-97.
2008: Honkavuori Maria; Talvensaari-Mattila Anne; Puistola Ulla; Turpeenniemi-Hujanen Taina; Santala Markku
High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Anticancer research 2008;28(5A):2715-9.
2008: Kuvaja Paula; Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina
High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma.
International journal of cancer. Journal international du cancer 2008;123(4):846-51.
2008: Sihto Harri; Lundin Johan; Lehtimäki Tiina; Sarlomo-Rikala Maarit; Bützow Ralf; Holli Kaija; Sailas Liisa; Kataja Vesa; Lundin Mikael; Turpeenniemi-Hujanen Taina; Isola Jorma; Heikkilä Päivi; Joensuu Heikki
Molecular subtypes of breast cancers detected in mammography screening and outside of screening.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4103-10.
2008: Vasala Kaija; Pääkko Paavo; Turpeenniemi-Hujanen Taina
Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Anticancer research 2008;28(3B):1757-61.
2008: Väisänen Anne H; Kallioinen Matti; Turpeenniemi-Hujanen Taina
Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Human pathology 2008;39(3):377-85.
2008: Pennanen Heli; Kuittinen Outi; Turpeenniemi-Hujanen Taina
Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
European journal of haematology 2008;80(1):46-54.
2007: Määtta Milla; Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina; Santala Markku
Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Anticancer research 2007;27(4C):2753-8.
2007: Vasala Kaija; Turpeenniemi-Hujanen Taina
Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
Clinical biochemistry 2007;40(9-10):640-4.
2007: Sillanpää S; Anttila M; Voutilainen K; Ropponen K; Turpeenniemi-Hujanen T; Puistola U; Tammi R; Tammi M; Sironen R; Saarikoski S; Kosma V-M
Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.
Gynecologic oncology 2007;104(2):296-303.
2007: Honkavuori M; Talvensaari-Mattila A; Soini Y; Turpeenniemi-Hujanen T; Santala M
MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma.
Gynecologic oncology 2007;104(1):217-21.
2007: Kuvaja P; Würtz S Ø; Talvensaari-Mattila A; Brünner N; Pääkkö P; Turpeenniemi-Hujanen T
High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study.
Cancer biomarkers : section A of Disease markers 2007;3(6):293-300.
2007: Sillanpää S; Anttila M; Suhonen K; Hämäläinen K; Turpeenniemi-Hujanen T; Puistola U; Tammi M; Sironen R; Saarikoski S; Kosma V-M
Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2007;28(5):280-9.
2006: Lundin Johan; Lehtimäki Tiina; Lundin Mikael; Holli Kaija; Elomaa Liisa; Turpeenniemi-Hujanen Taina; Kataja Vesa; Isola Jorma; Joensuu Heikki
Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series.
European journal of cancer (Oxford, England : 1990) 2006;42(18):3228-35.
2006: Rauvala Marita; Turpeenniemi-Hujanen Taina; Puistola Ulla
The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
Anticancer research 2006;26(6C):4779-84.
2006: Kuvaja Paula; Talvensaari-Mattila Anne; Pääkkö Paavo; Turpeenniemi-Hujanen Taina
Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
Human pathology 2006;37(10):1316-23.
2006: Mackey Abigail L; Donnelly Alan E; Swanton Alan; Murray Fiona; Turpeenniemi-Hujanen Taina
The effects of impact and non-impact exercise on circulating markers of collagen remodelling in humans.
Journal of sports sciences 2006;24(8):843-8.
2006: Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Cancer letters 2006;236(1):125-32.
2006: Joensuu Heikki; Kellokumpu-Lehtinen Pirkko-Liisa; Bono Petri; Alanko Tuomo; Kataja Vesa; Asola Raija; Utriainen Tapio; Kokko Riitta; Hemminki Akseli; Tarkkanen Maija; Turpeenniemi-Hujanen Taina; Jyrkkiö Sirkku; Flander Martti; Helle Leena; Ingalsuo Seija; Johansson Kaisu; Jääskeläinen Anna-Stina; Pajunen Marjo; Rauhala Mervi; Kaleva-Kerola Jaana; Salminen Tapio; Leinonen Mika; Elomaa Inkeri; Isola Jorma;
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
The New England journal of medicine 2006;354(8):809-20.
2006: Ruokolainen Henni; Pääkkö Paavo; Turpeenniemi-Hujanen Taina
Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2006;19(2):208-17.
2005: Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Gynecologic oncology 2005;99(3):656-63.
2005: Talvensaari-Mattila Anne; Santala Markku; Soini Ylermi; Turpeenniemi-Hujanen Taina
Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
Anticancer research 2005;25(6B):4101-5.
2005: Kuittinen T; Wiklund T; Remes K; Elonen E; Lehtinen T; Kuittinen O; Leppä S; Putkonen M; Räty R; Turpeenniemi-Hujanen T; Nousiainen T; Jantunen E
Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey.
European journal of haematology 2005;75(3):199-205.
2005: Ruokolainen Henni; Pääkkö Paavo; Turpeenniemi-Hujanen Taina
Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker.
International journal of cancer. Journal international du cancer 2005;116(3):422-7.
2005: Ruokolainen Henni; Pääkkö Paavo; Turpeenniemi-Hujanen Taina
Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3257-64.
2005: Sivula Anna; Talvensaari-Mattila Anne; Lundin Johan; Joensuu Heikki; Haglund Caj; Ristimäki Ari; Turpeenniemi-Hujanen Taina
Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
Breast cancer research and treatment 2005;89(3):215-20.
2005: Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina
High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma.
Breast cancer research and treatment 2005;89(1):29-34.
2005: Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina
Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma.
Cancer letters 2005;217(2):237-42.
2005: Kuvaja Paula; Talvensaari-Mattila Anne; Pääkkö Paavo; Turpeenniemi-Hujanen Taina
The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma.
Oncology 2005;68(2-3):196-203.
2004: Rahko Eeva; Jukkola Arja; Melkko Jukka; Paavo Pääkkö; Bloigu Risto; Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina
Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy.
Anticancer research 2004;24(6):4247-53.
2004: Aglund Kristina; Rauvala Marita; Puistola Ulla; Angström Tord; Turpeenniemi-Hujanen Taina; Zackrisson Björn; Stendahl Ulf
Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage.
Gynecologic oncology 2004;94(3):699-704.
2004: Joensuu Heikki; Lehtimäki Tiina; Holli Kaija; Elomaa Liisa; Turpeenniemi-Hujanen Taina; Kataja Vesa; Anttila Ahti; Lundin Mikael; Isola Jorma; Lundin Johan
Risk for distant recurrence of breast cancer detected by mammography screening or other methods.
JAMA : the journal of the American Medical Association 2004;292(9):1064-73.
2004: Määttä M; Santala M; Soini Y; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(4):188-92.
2004: Mackey Abigail L; Donnelly Alan E; Turpeenniemi-Hujanen Taina; Roper Helen P
Skeletal muscle collagen content in humans after high-force eccentric contractions.
Journal of applied physiology (Bethesda, Md. : 1985) 2004;97(1):197-203.
2004: Outi Kuittinen; Järvinen Mikko; Soini Ylermi; Weber Ekkehard; Turpeenniemi-Hujanen Taina; Blanco Guillermo
Changing prognostic role of preserved dendritic cell reticulum in Hodgkin's lymphoma.
Leukemia & lymphoma 2004;45(5):1081-2.
2004: Ruokolainen Henni; Pääkkö Paavo; Turpeenniemi-Hujanen Taina
Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):3110-6.
2004: Pennanen Heli; Kuittinen Outi; Soini Ylermi; Turpeenniemi-Hujanen Taina
Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma.
European journal of haematology 2004;72(1):1-9.
2003: Vasala Kaija; Pääkkö Paavo; Turpeenniemi-Hujanen Taina
Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer.
Urology 2003;62(5):952-7.
2003: Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma.
British journal of cancer 2003;89(7):1270-5.
2003: Kuittinen Outi; Apaja-Sarkkinen Meeri; Turpeenniemi-Hujanen Taina
Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.
European journal of haematology 2003;71(2):91-9.
2003: Joensuu Heikki; Isola Jorma; Lundin Mikael; Salminen Tiina; Holli Kaija; Kataja Vesa; Pylkkänen Liisa; Turpeenniemi-Hujanen Taina; von Smitten Karl; Lundin Johan
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):923-30.
2003: Hirvonen Riikka; Talvensaari-Mattila Anne; Pääkkö Paavo; Turpeenniemi-Hujanen Taina
Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma.
Breast cancer research and treatment 2003;77(1):85-91.
2002: Kuittinen Outi; Soini Ylermi; Turpeenniemi-Hujanen Taina
Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.
European journal of haematology 2002;69(4):205-12.
2001: Kuittinen O; Ruokolainen H; Turpeenniemi-Hujanen T
Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro.
Leukemia & lymphoma 2001;42(3):507-10.
2001: Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula V L; Turpeenniemi-Hujanen T; Jukkola A
Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1633-7.
2001: Kuittinen O; Savolainen E R; Koistinen P; Möttönen M; Turpeenniemi-Hujanen T
MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL).
Leukemia research 2001;25(2):125-31.
2001: Talvensaari-Mattila A; Pääkko P; Blanco-Sequeiros G; Turpeenniemi-Hujanen T
Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy.
Breast cancer research and treatment 2001;65(1):55-61.
2001: Lundin J; Lundin M; Holli K; Kataja V; Elomaa L; Pylkkänen L; Turpeenniemi-Hujanen T; Joensuu H
Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(1):28-36.
2000: Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Anticancer research 2000;20(2B):1311-6.
2000: Jäälinojä J; Herva R; Korpela M; Höyhtyä M; Turpeenniemi-Hujanen T
Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms.
Journal of neuro-oncology 2000;46(1):81-90.
1999: Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.
Breast cancer research and treatment 1999;58(3):287-93.
1999: Ylisirniö S; Sassi M L; Risteli J; Turpeenniemi-Hujanen T; Jukkola A
Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.
Anticancer research 1999;19(6C):5577-81.
1999: Westerlund A; Apaja-Sarkkinen M; Höyhtyä M; Puistola U; Turpeenniemi-Hujanen T
Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer.
Gynecologic oncology 1999;75(1):91-8.
1999: Kuittinen O; Savolainen E R; Koistinen P; Turpeenniemi-Hujanen T
Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML.
Anticancer research 1999;19(5C):4395-400.
1999: Väisänen A; Kallioinen M; von Dickhoff K; Laatikainen L; Höyhtyä M; Turpeenniemi-Hujanen T
Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma?
The Journal of pathology 1999;188(1):56-62.
1998: Väisänen A; Kallioinen M; Taskinen P J; Turpeenniemi-Hujanen T
Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
The Journal of pathology 1998;186(1):51-8.
1998: Talvensaari-Mattila A; Pääkkö P; Höyhtyä M; Blanco-Sequeiros G; Turpeenniemi-Hujanen T
Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma.
Cancer 1998;83(6):1153-62.
1997: Westerlund A; Hujanen E; Puistola U; Turpeenniemi-Hujanen T
Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2).
Gynecologic oncology 1997;67(1):76-82.
1997: Westerlund A; Hujanen E; Höyhtyä M; Puistola U; Turpeenniemi-Hujanen T
Ovarian cancer cell invasion is inhibited by paclitaxel.
Clinical & experimental metastasis 1997;15(3):318-28.
1996: Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
The Journal of pathology 1996;180(3):283-9.
1995: Rämet M; Castrén K; Järvinen K; Pekkala K; Turpeenniemi-Hujanen T; Soini Y; Pääkkö P; Vähäkangas K
p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines.
Carcinogenesis 1995;16(9):2117-24.
1995: Puistola U; Westerlund A; Kauppila A; Turpeenniemi-Hujanen T
Regulation of 72-kd type IV collagenase-matrix metalloproteinase-2 by estradiol and gonadotropin-releasing hormone agonist in human granulosa-lutein cells.
Fertility and sterility 1995;64(1):81-7.
1995: Turpeenniemi-Hujanen T; Feinberg R F; Kauppila A; Puistola U
Extracellular matrix interactions in early human embryos: implications for normal implantation events.
Fertility and sterility 1995;64(1):132-8.
1994: Kamel D; Turpeenniemi-Hujanen T; Vähäkangas K; Pääkkö P; Soini Y
Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma.
Histopathology 1994;25(4):339-47.
1994: Hujanen E S; Väisänen A; Zheng A; Tryggvason K; Turpeenniemi-Hujanen T
Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma.
International journal of cancer. Journal international du cancer 1994;58(4):582-6.
1993: Soini Y; Turpeenniemi-Hujanen T; Kamel D; Autio-Harmainen H; Risteli J; Risteli L; Nuorva K; Pääkkö P; Vähäkangas K
p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression.
British journal of cancer 1993;68(5):1029-35.
1992: Turpeenniemi-Hujanen T; Rönnberg L; Kauppila A; Puistola U
Laminin in the human embryo implantation: analogy to the invasion by malignant cells.
Fertility and sterility 1992;58(1):105-13.
1991: Hujanen E S; Turpeenniemi-Hujanen T
Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro.
International journal of cancer. Journal international du cancer 1991;47(4):576-81.
1991: Myllylä R; Pihlajaniemi T; Pajunen L; Turpeenniemi-Hujanen T; Kivirikko K I
Molecular cloning of chick lysyl hydroxylase. Little homology in primary structure to the two types of subunit of prolyl 4-hydroxylase.
The Journal of biological chemistry 1991;266(5):2805-10.
1990: Höyhtyä M; Hujanen E; Turpeenniemi-Hujanen T; Thorgeirsson U; Liotta L A; Tryggvason K
Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase.
International journal of cancer. Journal international du cancer 1990;46(2):282-6.
1989: Puistola U; Rönnberg L; Martikainen H; Turpeenniemi-Hujanen T
The human embryo produces basement membrane collagen (type IV collagen)-degrading protease activity.
Human reproduction (Oxford, England) 1989;4(3):309-11.
1988: Höyhtyä M; Turpeenniemi-Hujanen T; Stetler-Stevenson W; Krutzsch H; Tryggvason K; Liotta L A
Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin.
FEBS letters 1988;233(1):109-13.
1984: Turpeenniemi-Hujanen T; Myllylä R
Concomitant hydroxylation of proline and lysine residues in collagen using purified enzymes in vitro.
Biochimica et biophysica acta 1984;800(1):59-65.
1981: Turpeenniemi-Hujanen T M; Puistola U; Kivirikko K I
Human lysyl hydroxylase: purification to homogeneity, partial characterization and comparison of catalytic properties with those of a mutant enzyme from Ehlers-Danlos syndrome type VI fibroblasts.
Collagen and related research 1981;1(4):355-66.
1980: Turpeenniemi-Hujanen T M; Puistola U; Kivirikko K I
Isolation of lysyl hydroxylase, an enzyme of collagen synthesis, from chick embryos as a homogeneous protein.
The Biochemical journal 1980;189(2):247-53.
1980: Puistola U; Turpeenniemi-Hujanen T M; Myllylä R; Kivirikko K I
Studies on the lysyl hydroxylase reaction. II. Inhibition kinetics and the reaction mechanism.
Biochimica et biophysica acta 1980;611(1):51-60.
1980: Puistola U; Turpeenniemi-Hujanen T M; Myllylä R; Kivirikko K I
Studies on the lysyl hydroxylase reaction. I. Initial velocity kinetics and related aspects.
Biochimica et biophysica acta 1980;611(1):40-50.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Taina Turpeenniemi-Hujanen

Research Profile (preview)

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Taina Turpeenniemi-Hujanen (preview)

All Publications